Biomarkers to Determine Who Gets Checkpoint Inhibitors
Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.
Source: Medscape Oncology - Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
More News: Cancer & Oncology